, Volume 58, Issue 2, pp 312–312 | Cite as


A Viewpoint by Siva Subramanian
  • Siva Subramanian
Adis New Drug Profile Guest Commentary


  1. 1.
    Siva Subramanian KN, Weisman LE, Rhodes T et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17: 110–5CrossRefGoogle Scholar
  2. 2.
    IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531–7CrossRefGoogle Scholar
  3. 3.
    Conor EM, Carlin D, Top FH et al. Questions about Palivizumab (Synagis). Reply. Pediatrics 1999; 103: 535Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Siva Subramanian
    • 1
  1. 1.Division Pediatrics and Obstetrics and GynaecologyGeorgetown University Medical CentresWashington, DCUSA

Personalised recommendations